ONLY IDELVION IS FDA APPROVED FOR UP TO 14-DAY DOSING

IDELVION offers individualized prophylaxis dosing with up to 14-day dosing in patients ≥12 years

ADULTS AND ADOLESCENTS
Start on 7-day dosing (25-40 IU/kg)
right arrow
down arrow
Once well controlled move to 14-day dosing (50-75 IU/kg)
PEDIATRIC PATIENTS
7-day dosing (40-55 IU/kg)

Choose the regimen that’s right for your patients and adjust based on their clinical condition and response.

*In patients 12 years and older on a weekly dose of ≤40 IU/kg for 1 month while not requiring dose adjustments or experiencing spontaneous bleeding.

ON-DEMAND DOSING
PERIOPERATIVE DOSING
Type of Bleeding Episode Circulating Factor IX Activity Required (% or IU/dL) Frequency of Dosing (hours) Duration of Therapy (days)
MINOR OR MODERATE Uncomplicated hemarthrosis, muscle bleeding (except iliopsoas) or oral bleeding 30–60 48–72 At least 1 day, until bleeding stops and healing is achieved. Single dose should be sufficient for majority of bleeds.
MAJOR Life or limb threatening hemorrhage, deep muscle bleeding, including iliopsoas, intracranial, retropharyngeal 60–100 48–72 7–14 days, until bleeding stops and healing is achieved. Maintenance dose weekly.
Type of Bleeding Episode
MINOR OR MODERATE Uncomplicated hemarthrosis, muscle bleeding (except iliopsoas) or oral bleeding MAJOR Life or limb threatening hemorrhage, deep muscle bleeding, including iliopsoas, intracranial, retropharyngeal
Circulating Factor IX Activity Required (% or IU/dL)
30–60 60–100
Frequency of Dosing (hours)
48–72 48–72
Duration of Therapy (days)
At least 1 day, until bleeding stops and healing is achieved. Single dose should be sufficient for majority of bleeds. 7–14 days, until bleeding stops and healing is achieved. Maintenance dose weekly.
Type of Surgery Circulating Factor IX Activity Required (% or IU/dL) Frequency of Dosing (hours) Duration of Therapy (days)
MINOR (including uncomplicated tooth extraction) 50–80 48–72 At least 1 day, or until healing is achieved. Single dose should be sufficient for a majority of minor surgeries.
MAJOR (including intracranial, pharyngeal, retropharyngeal, retroperitoneal) 60–100
(initial level)
48–72 7–14 days, or until bleeding stops and healing is achieved. Repeat dose every 48–72 hours for the first week or until healing is achieved. Maintenance dose 1–2 times per week.
Type of Surgery
MINOR (including uncomplicated tooth extraction) MAJOR (including intracranial, pharyngeal, retropharyngeal, retroperitoneal)
Circulating Factor IX Activity Required (% or IU/dL)
50–80 60–100
(initial level)
Frequency of Dosing (hours)
48–72 48–72
Duration of Therapy (days)
At least 1 day, or until healing is achieved. Single dose should be sufficient for a majority of minor surgeries. 7–14 days, or until bleeding stops and healing is achieved. Repeat dose every 48–72 hours for the first week or until healing is achieved. Maintenance dose 1–2 times per week.

†Adapted from the WFH Guidelines for the Management of Hemophilia.

More vial sizes may mean less to reconstitute and infuse

5 vial sizes for optimal flexibility and efficiency

  • A range of sizes to facilitate the regimen you choose
  • Reconstituting is fast and simple using the Mix2Vial® needle-free reconstitution and transfer system

No refrigeration required

  • May be stored at room temperature or in refrigerator (36°F–77°F). Do not freeze
  • Do not store past expiration date printed on carton and vial
IDELVION 250 IU vial size for dosing flexibility

KIT NDC: 69911-864-02 2.5-mL diluent

IDELVION 500 IU vial size for dosing flexibility

KIT NDC: 69911-865-02 2.5-mL diluent

IDELVION 1000 IU vial size for dosing flexibility

KIT NDC: 69911-866-02 2.5-mL diluent

IDELVION 2000 IU vial size for dosing flexibility

KIT NDC: 69911-867-02 5-mL diluent

IDELVION 3500 IU vial size for dosing flexibility

KIT NDC: 69911-869-02 5-mL diluent

Images are representations, not actual depictions of actual vials.

Mix2Vial® is a registered trademark of West Pharma Services IL, Ltd., a subsidiary of West Pharmaceuticals Services, Inc.

When switching to IDELVION, Ray made the transition from on-demand to an extended prophylaxis regimen

Extending dosing let me work with my doctor to develop a dosing schedule that works for me.

Watch Ray’s full story
21% trough levels with prophylactic use

IDELVION delivers high Factor IX trough levels at steady state on 7-day dosing1

SEE IDELVION FACTOR IX LEVELS
0 spontaneous bleeds


Achieved in adults and adolescents dosing at 7 or 14 days in pivotal trials

VIEW EFFICACY DATA

Reference: 1. Gill JC, Roberts J, Li Y, Castaman G. Sustained high trough factor IX activity levels with continued use of rIX-FP in adult and paediatric patients with haemophilia B. Haemophilia. 2019. doi:10.1111/hae.13735.

X
You are now leaving the current website.

Do you want to continue?